Background: Continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring systems (CGMS) have been proven very effective in diabetes management. Aim: This study evaluated the usefulness of these devices during prolonged, intense physical activity in an uncontrolled natural environment away from the clinical research center. Design: Non-randomized, prospective and observational study. Methods: During the summer, 38 participants with type 1 diabetes crossed the Samaria gorge, the second largest gorge in Europe (17 km). Twenty subjects on CSII combined with real-time CGMS and 18 on multiple daily injections (MDI) combined with professional (retrospective) CGMS participated in the program. All participants were unsupervised during the event.
Introduction
Intensive insulin therapy, either with multiple daily injections (MDI) or with continuous subcutaneous insulin infusion (CSII), combined with frequent self-monitoring of blood glucose (SMBG) is the cornerstone for the management of type 1 diabetes mellitus (T1DM). 1 Over the last few years, technological advances in glucose monitoring, including real-time and professional (retrospective) continuous glucose monitoring systems (CGMS), as well as threshold suspend device systems, have been proven very effective in optimizing glycemic control. 2, 3 Physical activity is a very important part of young people's lifestyle, but many patients with T1DM experience difficulties on how to control their blood sugar levels during exercise. It is widely recognized that physical activity can cause disturbances in blood glucose with hypoglycemia being the main concern for people with diabetes who exercise. 4 Furthermore, late-onset hypoglycemia can occur several hours after the completion of unusually strenuous exercise. 5, 6 At the same time, strenuous exercise is known to increase glucose production from the liver and insufficient insulin coverage can induce ketogenesis. 7 Fear of hypoglycemia and loss of control over diabetes have been identified as the major factors that lead people with T1DM to abstain from exercise. 8 Recent cross-sectional studies have indicated that more than 60% of the patients with T1DM do not exercise at all. 9 In literature, many studies have demonstrated the benefits of both CSII and real-time CGMS on daily glucose profile in patients with T1DM, but there are limited data regarding the usefulness of such devices during intense physical activity. [10] [11] [12] Also, it has not been elucidated how strenuous exercise influences glucose metabolism in T1DM, outside of the controlled environment of a clinical research center.
The aim of the present observational study was to evaluate the impact of CSII combined with real-time CGMS on glucose management, during and after intense exercise, in T1DM. In order to investigate the usefulness of these devices in 'real life', 38 adolescents and young adults with T1DM crossed the Samaria gorge, covering a total distance of 17 km. Twenty subjects used CSII combined with real-time CGMS and 18 MDI with professional (retrospective) CGMS participated in this prolonged exercise program. All participants were unsupervised during the exercise event.
Materials and Methods

Study design and population
A total of 38 participants with T1DM crossed the Samaria gorge during late summer. The Samaria gorge is in southwest Crete and is the second largest in Europe. It is 13 km long, starting at an altitude of 1250 m at the northern entrance, and ending at the Libyan Sea. There is a 2.5 km entrance to the gauge and a 1.5 km exit. Twenty subjects used the Medtronic Veo insulin pump (MiniMed 530G, Medtronic Diabetes, Northridge, CA) combined with real-time CGM and 18 subjects used MDI combined with professional (retrospective) CGMS (iPro, Medtronic Diabetes, Northridge, CA). Both groups used the Enlite 2 sensor. Participants were asked to calibrate the CGMS at least three times per day, according to the manufacturer's specifications. Participants walked as a mixed group. Medical staff consisted of four physicians accompanied the participants to assist only in the event of an emergency.
Two participants from the CSII and three from the MDI group lost their sensors during, or after exercise. The participants' clinical characteristics are summarized in Table 1 . The individuals who lost their sensors are not included in the table. All participants were C-peptide negative according to their records. Hypoglycemia awareness status was assessed using the Gold Score. 13 The study was carried out in accordance with the principles of the Declaration of Helsinki, as revised in 2013. 14 All participants gave their written informed consent for participation in the study and the use of their data for research purposes. Data from real-time or retrospective CGMS were downloaded the day following the end of the event. The frequency and duration of hypoglycemic episodes, as well as biochemical hypoglycemia exposure [area under the curve (AUC) 70 mg/dl calculated from CGMS data] were analyzed. A valid hypoglycemic episode was defined as blood glucose levels 70 mg/dl for !20 min, a blood glucose reading 70 mg/dl or where symptoms of hypoglycemia resolved with administration of carbohydrates. Analysis of hyperglycemic exposure (AUC >140 mg/dl) and the time spent above 180 mg/dl was estimated. Data from the day and the night (mid-night to 7 a.m.) after the event were included in the analysis.
Participants on CSII were instructed to reduce their basal insulin dose by 50% during the day as well as the night after the exercise event and respectively, their bolus insulin dose by 30%. Sensor alarms limits were set at 70 and 180 mg/dl to signal hypoglycemia or hyperglycemia, respectively. The low glucose suspend (LGS) feature of the Veo insulin pump was programmed to suspend insulin delivery at sensor glucose values 60 mg/dl. Participants on MDI were instructed to reduce their basal insulin dose by 30% the night before and by 50% the night after the exercise event. 15 Additionally, they were advised to reduce their bolus insulin dose by 30% for the same period. Participants on MDI were instructed to check their BG at least hourly. All participants adjusted their prandial insulin dosage by carbohydrate counting. In the morning, before starting the Associations between categorical variables were tested with the use of contingency tables and the calculation of the Chi-square test. Multivariate linear regression analysis was performed to assess the possible combined influence of the different variables on hypoglycemia incidence. All statistical tests were performed by using SPSS v18.0 (SPSS Inc., Chicago, IL, USA).
Results
All 38 participants managed to reach the destination point safely. The five individuals who lost their sensors were not included in the analysis ( Table 2 ). The duration of the exercise (mean 6 standard deviation) was 6.4 6 1.3 h and there was no difference between the two groups (6.3 6 0.9 vs. 6.5 6 1.7 h; P ¼ 0.71). The mean glucose level in the morning before exercise was 151.9 6 67 in the CSII group vs. 139.1 6 76 mg/dl in the MDI group (P ¼ 0.65). During the exercise event, plasma glucose levels did not fall significantly in most of the subjects of both groups; however, the mean number of hypoglycemic episodes was 0.1 6 0.3 in the CSII group vs. 0.4 6 0.6 in the MDI group, which was statistically significant (P ¼ 0.047). The total number of hypoglycemic episodes during the 24 h of the exercise event was 0.8 6 0.9 in the CSII group vs. 1.4 6 1.2 in the MDI group (P ¼ 0.13). The mean activation of the "low glucose suspend" feature of the Veo pump was 1.2 6 0.9 times/day. Also, for the same period, there were no differences in the time spent below 70 mg/dl (1. Regarding nocturnal hypoglycemia, the CSII group experienced 0.4 6 0.7 and the MDI group 0.6 6 0.9 episodes (P ¼ 0.53). Also, there were no differences in the time spent below 70 mg/dl during the night (0.4 6 0.7 vs. 0.7 6 1.7 h; P ¼ 0.54). Fewer subjects in the CSII group than in the MDI group reported hypoglycemia episodes during exercise (2/18 vs. 5/15; P ¼ 0.032). However, there was no significant difference between the two groups regarding the number of subjects who reported hypoglycemia episodes during the whole day (9/18 vs. 10/15; P ¼ 0.33) and the night after the exercise event (6/18 vs. 7/15; P ¼ 0.43).
Discussion
The present study demonstrated that the use of insulin pump technology by people with T1DM can help to limit hypoglycemia induced by strenuous prolonged exercise in an uncontrolled environment. The participants who used CSII combined with realtime CGMS exhibited significantly lower hypoglycemic episodes during exercise as well as lower AUC below 70 mg/dl compared with subjects on MDI during the 24 h of the exercise event. It was also presented that individuals on CSII combined with CGMS were significantly less likely to develop a hypoglycemic episode during exercise.
Although there are several studies in literature in which different strategies have been proposed to prevent hypoglycemia associated with exercise, [16] [17] [18] [19] [20] [21] [22] great uncertainty still exists on how to maintain euglycemia during extremely prolonged exercise, where many different external factors could influence blood glucose concentrations. To the best of our knowledge, there is only one study comparing the efficacy of sensoraugmented CSII and MDI, under the 'real-life' conditions of strenuous physical activity lasting many hours. However, in that study, only five participants were on CSII and all of them were very experienced to practice regular physical activities. 23 Hot climate conditions could limit the ability to exercise, especially when using CSII and disrupt glucose homeostasis. Moreover, excessive sweating could have displaced the subcutaneous infusion set. In the present study, no infusion set displacement was reported however, two participants from the CSII and three from the MDI group lost their sensors during, or after the exercise event. It is remarkable that all participants of the study managed to reach the finishing line safely. It must be noted that a recent observational study has shown that modern insulin pumps as well as CGMS work properly even at high altitudes and extremely low temperatures. 24 Furthermore, there are no available studies to support the superiority of CSII coupled with real-time CGMS over MDI with conventional SGM, in terms of hypoglycemia during or after prolonged, intense exercise. Real-time CGMS enables people with diabetes to review recent glucose trends and receive hypoglycemia alarms which could help them to detect and minimize hypoglycemic episodes. Moreover, the LGS feature of the VEO insulin pump, automatically suspends basal insulin delivery when the sensor glucose value reaches a preset threshold. 25, 26 In addition, it has been shown that CSII users can infuse insulin more precisely comparing to MDI, especially before meals when using the 'Bolus Wizard' feature. 27 In the present study, participants from the CSII group used a significantly less amount of insulin (2.8 6 1.9 vs. 5.6 6 2.2 IU) to cover the breakfast, which could have protected them from hypoglycemia during exercise. It must be noted that all participants were advised to reduce the amount of pre-prandial insulin to cover the breakfast by 30%, which, in combination with the reduction of basal insulin resulted, for some of them, in relatively high blood glucose levels, particularly during the first hour of exercise. However, in other relevant studies such an effect has not been reported, despite the greater reduction of insulin dosage. 17, 20 Consumption of large quantities of High Glycemic Index carbohydrates must be avoided and Low Glycemic Index carbohydrates must be preferred, before such type of exercise in order to improve glucose control during exercise. 28 Careful attentions must also be given when treating low blood glucose levels since many hyperglycemic incidents were preceded by hypoglycemic events. Our results demonstrated that despite the marked reduction of the basal and pre-prandial insulin by 50% and 30% respectively, exercise-induced nocturnal hypoglycemia was not prevented effectively in either the CSII or the MDI group. One has to take in consideration that this is a real-life observation of the potential benefit of technology in strenuous prolonged exercise. Thus, there are several limitations of the study. The major limitation is that it was not randomized. Furthermore, participants were not closely supervised during the exercise event, which, could potentially lead to bias in the interpretation of the results. However, clinical studies in 'reallife' conditions testing CSII during prolonged exercise are lacking. On the other hand, observational studies in 'real-life' settings can be very valuable when comparing the efficacy and effectiveness of different approaches to treatment of diabetes. 29 It must be highlighted that there was big interindividual variability in the efficacy of CSII, which indicates that there were differences in the quality of diabetes education between the participants. High individual variability can also exist in the blood glucose responses to different forms of exercise. 9 Additional limitation of the study is that due to its design, it was very difficult to determine if the CSII or the CGMS contributed the most to the reduction of hypoglycemia. The impact of AUC below 54 mg/dl has not been analyzed.
Finally, the study did not assess whether the lag time between blood glucose and interstitial glucose levels, which can be up to 15 min, influenced patients' decision toward insulin adjustments or carbohydrate intake. 25 In summary, CSII combined with CGMS demonstrated to be useful tool for people with T1DM who perform prolonged, strenuous, exercise. It was shown that the use of diabetes technology in regions with hot Mediterranean climates is safe and can provide long term protection against exercise-induced hypoglycemia. Further studies must be conducted, to create precise instructions for people with T1DM who occasionally are involved in exercise activities in real life.
